Adjuvant Comparison and Characterization (HIV)

NIH Pandemic-Era Grants

Pandemic Era Grants

2023

↗ Live URL (may be dead)

Document text

Principal Investigator: BALI  PULENDRAN
Organization: STANFORD UNIVERSITY
Fiscal Year: 2023
Award: $1,780,989
Funding agency: National Institute of Allergy and Infectious Diseases

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms. A major challenge for HIV vaccine development is learning how to induce robust and durable antibody responses that protect against mucosal infection. A critical step on the path to overcoming this challenge are developing adjuvants that appropriately stimulate robust and durable immune responses. The goal of this project is to assess the impact of 3 different adjuvants on enhancing the magnitude and durability of neutralizing antibody responses against HIV Env.

Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adjuvant><Antibody Response><Antigens><Body Tissues><Encapsulated><Fingerprint><Gel><Goals><HIV><HIV vaccine><HIV/AIDS Vaccines><Human Immunodeficiency Viruses><Immune><Immune response><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Infection><LAV-HTLV-III><Learning><Lymphadenopathy-Associated Virus><Mucosa><Mucosal Tissue><Mucous Membrane><Side><Tissues><Vaccines><Virus-HIV><Work><clinical relevance><clinically relevant><develop a vaccine><develop vaccines><development of a vaccine><host response><human immunodeficiency virus vaccine><immune system response><immunogen><immunoresponse><lipid based nanoparticle><lipid nanoparticle><neutralizing antibody><non-human primate><nonhuman primate><programs><vaccine development>